CA2670498A1 - Combination of iap inhibitors and flt3 inhibitors - Google Patents

Combination of iap inhibitors and flt3 inhibitors Download PDF

Info

Publication number
CA2670498A1
CA2670498A1 CA002670498A CA2670498A CA2670498A1 CA 2670498 A1 CA2670498 A1 CA 2670498A1 CA 002670498 A CA002670498 A CA 002670498A CA 2670498 A CA2670498 A CA 2670498A CA 2670498 A1 CA2670498 A1 CA 2670498A1
Authority
CA
Canada
Prior art keywords
alkyl
aryl
substituted
het
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002670498A
Other languages
English (en)
French (fr)
Inventor
James Douglas Griffin
Leigh Zawel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Dana Farber Cancer Institute Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2670498A1 publication Critical patent/CA2670498A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002670498A 2006-11-28 2007-11-27 Combination of iap inhibitors and flt3 inhibitors Abandoned CA2670498A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86744806P 2006-11-28 2006-11-28
US60/867,448 2006-11-28
US89108807P 2007-02-22 2007-02-22
US60/891,088 2007-02-22
PCT/US2007/085579 WO2008067280A2 (en) 2006-11-28 2007-11-27 Combination of iap inhibitors and flt3 inhibitors

Publications (1)

Publication Number Publication Date
CA2670498A1 true CA2670498A1 (en) 2008-06-05

Family

ID=39386468

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002670498A Abandoned CA2670498A1 (en) 2006-11-28 2007-11-27 Combination of iap inhibitors and flt3 inhibitors

Country Status (20)

Country Link
US (1) US8492429B2 (cg-RX-API-DMAC10.html)
EP (1) EP2089024B1 (cg-RX-API-DMAC10.html)
JP (1) JP5394249B2 (cg-RX-API-DMAC10.html)
KR (1) KR20090087094A (cg-RX-API-DMAC10.html)
AT (1) ATE509629T1 (cg-RX-API-DMAC10.html)
AU (1) AU2007325280B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0719543A2 (cg-RX-API-DMAC10.html)
CA (1) CA2670498A1 (cg-RX-API-DMAC10.html)
CO (1) CO6210722A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP099472A (cg-RX-API-DMAC10.html)
GT (1) GT200900142A (cg-RX-API-DMAC10.html)
IL (1) IL198551A0 (cg-RX-API-DMAC10.html)
MA (1) MA30966B1 (cg-RX-API-DMAC10.html)
MX (1) MX2009005621A (cg-RX-API-DMAC10.html)
NO (1) NO20092417L (cg-RX-API-DMAC10.html)
PL (1) PL2089024T3 (cg-RX-API-DMAC10.html)
PT (1) PT2089024E (cg-RX-API-DMAC10.html)
RU (1) RU2456983C2 (cg-RX-API-DMAC10.html)
TN (1) TN2009000206A1 (cg-RX-API-DMAC10.html)
WO (1) WO2008067280A2 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics, Inc. composto de ligação de domìnio bir da iap
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2296650B1 (en) 2008-05-16 2020-05-06 Novartis AG Immunomodulation by iap inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
JP2014528409A (ja) 2011-09-30 2014-10-27 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患（がん）の治療において使用するためのＳＭＡＣ模倣体（ビリナパント（ｂｉｒｉｎａｐａｎｔ））
KR20160030099A (ko) 2013-06-25 2016-03-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
EP3928780A4 (en) 2019-02-22 2022-12-07 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
JP2022522534A (ja) 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Ｐｒｍｔ５を標的にする化合物
EP3991733A4 (en) 2019-06-27 2023-07-05 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1453661A1 (ru) * 1972-11-17 1989-10-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Противоопухолевое средство "продимин
CA2491041A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
PL2253614T3 (pl) * 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
US20090005411A1 (en) 2005-12-20 2009-01-01 Novartic Ag Combinations of Organic Compounds
PE20110217A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
CO6210722A2 (es) 2010-10-20
JP5394249B2 (ja) 2014-01-22
RU2456983C2 (ru) 2012-07-27
TN2009000206A1 (en) 2010-10-18
JP2010511059A (ja) 2010-04-08
PT2089024E (pt) 2011-08-31
US20100056467A1 (en) 2010-03-04
PL2089024T3 (pl) 2011-10-31
ATE509629T1 (de) 2011-06-15
EP2089024A2 (en) 2009-08-19
BRPI0719543A2 (pt) 2014-02-25
WO2008067280A2 (en) 2008-06-05
RU2009124590A (ru) 2011-01-10
WO2008067280A3 (en) 2008-08-07
NO20092417L (no) 2009-08-25
IL198551A0 (en) 2010-02-17
AU2007325280B2 (en) 2011-03-10
KR20090087094A (ko) 2009-08-14
ECSP099472A (es) 2009-10-30
MA30966B1 (fr) 2009-12-01
AU2007325280A1 (en) 2008-06-05
MX2009005621A (es) 2009-06-12
US8492429B2 (en) 2013-07-23
EP2089024B1 (en) 2011-05-18
GT200900142A (es) 2010-06-24

Similar Documents

Publication Publication Date Title
AU2007325280B2 (en) Combination of IAP inhibitors and FLT3 inhibitors
Mo et al. Human ABCG2: structure, function, and its role in multidrug resistance
AU2007342225A1 (en) Use of IAP inhibitors for the treatment of acute myeloid leukemia
EP2900657B1 (en) Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
US20160220569A1 (en) CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
CN107873032A (zh) 苯并氧氮杂*噁唑烷酮化合物及其使用方法
KR20210002015A (ko) Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
MX2009000713A (es) Inhibidores de jak para el tratamiento de trastornos mieloproliferativos.
TWI824010B (zh) 治療血癌之組合療法
KR20100017984A (ko) 7-(2,5-디히드로-4-이미다조[1,2-ａ]피리딘-3-일-2,5-디옥소-1ｈ-피롤-3-일)-9-플루오로-1,2,3,4-테트라히드로-2-(1-피페리디닐카르보닐)-피롤로[3,2,1-ｊｋ][1,4]벤조디아제핀에 의한 암 화학요법의 강화
CN119403808A (zh) 用于医学治疗的细胞周期蛋白依赖性激酶2抑制剂
EP1638574B1 (en) New pharmaceutical uses of staurosporine derivatives
AU2006236812A1 (en) Combinations, methods and compositions for treating cancer
KR20080038298A (ko) 아미노피리미딘 조절제 및 파네실 전이 효소 억제제를이용하는 ｆｌｔ３ 키나아제의 상승적 조절
CN113490497A (zh) 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物
von Mehren New therapeutic strategies for soft tissue sarcomas
WO2019143818A1 (en) Combination therapy for the treatment of cancer
ES2366299T3 (es) Combinación de inhibidores de iap e inhibidores flt3.
AU2005279344B2 (en) Use of midostaurin for treating gastrointestinal stromal tumors
JP2025143272A (ja) がんを処置する方法及び使用
Karampeazis et al. A phase I-II and pharmacokinetic study of imatinib mesylate in combination with irinotecan in patients with relapsed or refractory small-cell lung cancer
HK40043323A (en) Combination therapy for the treatment of cancer
HK1095519B (en) The use of staurosporine derivatives for the manufacture of a medicament

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150123